Potentiate Therapeutics harnesses decades of neurosteroid biology to build non-sedating therapies across neurology and psychiatry — led by our Essential Tremor program.
Harnessing decades of neurosteroid biology to discover non-sedating therapeutics for neurological and psychiatric disease.
Decades of target biology translated into intelligent drug design.
Structure-based and intuitive molecular design.
Brain exposure, safety, and PK/PD engineered in by design.
Biomarkers linking target engagement to clinical outcomes.
One of the most common movement disorders — where existing therapies work, but tolerability keeps patients from staying on them.
Uncontrolled shaking of the hands, head and voice — driving depression, isolation and unemployment.
Today's options are limited by side effects and high discontinuation within the first years of use.
A newly emerging approval sets a clear regulatory path — and confirms the commercial opportunity.
We didn't discover the biology — we engineered a better drug. 403-73-P1 restores the body's own neurosteroids to calm tremor, without the sedation that has held the class back.
One non-sedating mechanism — a pipeline of CNS opportunities across neurology and psychiatry, led by Essential Tremor.
Validated path · near-term value inflection.
Human-validated, non-sedating anxiolysis.
Preclinical proof-of-concept in neuropathic pain.
Strong neurosteroid mechanistic rationale.
Mood-circuit mechanism with rapid-onset potential.
Parkinson's & Alzheimer's — neurosteroid deficits.
Proven leaders in CNS drug discovery, clinical development, and company creation.
We're building the first generation of non-sedating neurosteroid therapies. For partnering, investment, or scientific collaboration, we'd love to hear from you.
info@potentiatetx.com